



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/575,836	02/09/2007	Claudine Elvire Marie Bruck	VB60529	5658

20462 7590 11/16/2007
SMITHKLINE BEECHAM CORPORATION
CORPORATE INTELLECTUAL PROPERTY-US, UW2220
P. O. BOX 1539
KING OF PRUSSIA, PA 19406-0939

EXAMINER
OGUNBIYI, OLUWATOSIN A

ART UNIT	PAPER NUMBER
1645	

NOTIFICATION DATE	DELIVERY MODE
11/16/2007	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

US_cipkop@gsk.com

Office Action Summary	Application No. 10/575,836	Applicant(s) BRUCK ET AL.	
	Examiner Oluwatosin Ogunbiyi	Art Unit 1645	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-29 and 36-42 is/are pending in the application.
 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) ____ is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☒ Claim(s) 1-29 and 36-42 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|--|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____ |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date ____ | 6) <input type="checkbox"/> Other: ____ |

DETAILED ACTION

Claims 1-29 and 36-42 are pending in the application. Claims 30-35 have been cancelled in the amendment entered into the record and filed 4/13/06.

Sequence Requirements

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. § 1.821-1.825 for the reason(s) set forth below. Full compliance with the sequence rules is required in response to this office action.

A paper copy and computer readable form for the sequences listed in the application has not been filed.

Claim Informalities

Claim 41 appears to be improperly dependent on claim 26 instead of claim 36. For the purposes of the restriction requirement below claim 41 has been placed with the product claims of Group III.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

- Group I, claim(s) 1,2,5-12 and 29 drawn to a method of enhancing an immune response to an antigen in a mammal comprising administering to the mammal a safe and effective amount of 1) an IL-18 polypeptide or bioactive fragment or

variant thereof and 2) an immunogenic composition comprising a tumor-associated antigen or immunogenic derivative thereof and a CpG adjuvant..

- Group II, claim(s) 3,4 and 36-40 drawn to a method of reducing the severity of cancer or a method of treating a patient suffering from or susceptible to autoimmune diseases, cancer, infectious diseases in a patient, comprising administering IL-8 and a CpG adjuvant.
- Group III, claim(s) 13-20, 21-28, 41 and 42 drawn to a combined preparation comprising as active ingredients the following individual components: (1) an IL-18 polypeptide or bioactive fragment or variant thereof and (2) immunogenic composition comprising an antigen and a CpG adjuvant, the active ingredients being for the simultaneous, separate or sequential use for the prophylaxis and/or treatment of cancer, infectious disease, autoimmune diseases and related conditions.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

- The technical feature of groups I is a method of enhancing an immune response to an antigen in a mammal, comprising administering to the mammal a safe and effective amount of 1) an IL-18 polypeptide or bioactive fragment or variant thereof, and 2) an immunogenic composition comprising an antigen or immunogenic derivative thereof and a CpG adjuvant.

Art Unit: 1645

- The technical feature of Group II is a method of reducing the severity of cancer or a method of treating a patient suffering from or susceptible to autoimmune diseases, cancer, infectious diseases in a patient, comprising administering IL-18 and a CpG adjuvant.
- The technical feature of Group III is a combined preparation comprising as active ingredients the following individual components: (1) an IL-18 polypeptide or bioactive fragment or variant thereof and (2) immunogenic composition comprising an antigen and a CpG adjuvant, the active ingredients being for the simultaneous, separate or sequential use for the prophylaxis and/or treatment of cancer, infectious disease, autoimmune diseases and related conditions.

The technical feature of Group I lacks unity with the technical feature of groups II-III because the technical feature of Group I is anticipated by the art and therefore not "special" within the meaning of PCT Rule 13.2 because it does not provide for a contribution that the claimed invention makes over the art. Levy et al (WO 01/68896 A1) teaches a method of enhancing the immune response to an antigen by administering an IL-18 protein and an antigen and CpG adjuvant (See abstract, p. 3 line 32 – p.4 line 6, p.6 line 4 – p.7 line 26, p.9 line 14 – 31 and p. 14 line 17- 22).

Species Election

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1. The species are as follows:

Art Unit: 1645

Group I

- Species of CpG adjuvant selected from: TCC ATG ACG TTC CTG ACG TT (SEQ ID NO:1); TCT CCC AGC GTG CGC CAT (SEQ ID NO:2); ACC GAT GAC GTC GCC GGT GAC GGC ACC ACG (SEQ ID NO:3); TCG TCG TTT TGT CGT TTT GTC GTT (SEQ ID NO:4); and TCC ATG ACG TTC CTG ATG CT (SEQ ID NO:5).
- Species of infectious disease antigen selected from: Human Immunodeficiency virus HIV-1, human herpes simplex viruses, cytomegalovirus, Rotavirus, Epstein Barr virus, Varicella Zoster Virus, from a hepatitis virus such as hepatitis B virus, hepatitis A virus, hepatitis C virus and hepatitis E virus, from Respiratory Syncytial virus, parainfluenza virus, measles virus, mumps virus, human papilloma viruses, flaviviruses or Influenza virus, from *Neisseria* spp, *Moraxella* spp, *Bordetella* spp; *Mycobacterium* spp., including *M. tuberculosis*; *Escherichia* spp, including enterotoxigenic *E. coli*; *Salmonella* spp.; *Listeria* spp; *Helicobacter* spp; *Staphylococcus* spp., including *S. aureus*, *S. epidermidis*; *Borrelia* spp; *Chlamydia* spp., including *C. trachomatis*, *C. pneumoniae*; *Plasmodium* spp., including *P. falciparum*; *Toxoplasma* spp., and *Candida* spp.

Group II

- Species of disease selected from: cancer or infectious diseases or autoimmune diseases or related conditions
- Species of CpG adjuvant selected from: TCC ATG ACG TTC CTG ACG TT (SEQ ID NO:1); TCT CCC AGC GTG CGC CAT (SEQ ID NO:2); ACC GAT GAC GTC GCC GGT GAC GGC ACC ACG (SEQ ID NO:3); TCG TCG TTT TGT CGT TTT GTC GTT (SEQ ID NO:4); and TCC ATG ACG TTC CTG ATG CT (SEQ ID NO:5).
- Species of tumor associated antigen selected from MAGE family, PRAME, BAGE, LAGE 1, LAGE 2, SAGE, HAGE, XAGE, PSA, PAP, PSCA, prostatein,

Art Unit: 1645

P501 S, HASH2, Cripto, B726, NY-BR1.1, P510, MUC-1, Prostase, STEAP, tyrosinase, telomerase, survivin, CASB616, P53, and her 2 neu.

- Species of infectious disease antigen selected from: Human Immunodeficiency virus HIV-1, human herpes simplex viruses, cytomegalovirus, Rotavirus, Epstein Barr virus, Varicella Zoster Virus, from a hepatitis virus such as hepatitis B virus, hepatitis A virus, hepatitis C virus and hepatitis E virus, from Respiratory Syncytial virus, parainfluenza virus, measles virus, mumps virus, human papilloma viruses, flaviviruses or Influenza virus, from *Neisseria* spp, *Moraxelia* spp, *Bordetella* spp; *Mycobacterium* spp., including *M. tuberculosis*; *Escherichia* spp, including enterotoxigenic *E. coli*; *Salmonella* spp.; *Listeria* spp; *Helicobacter* spp; *Staphylococcus* spp., including *S. aureus*, *S. epidermidis*; *Borrelia* spp; *Chlamydia* spp., including *C. trachomatis*, *C. pneumoniae*; *Plasmodium* spp., including *P. falciparum*; *Toxoplasma* spp., and *Candida* spp.

Group III

- Species of disease selected from: cancer or infectious diseases or autoimmune diseases or related conditions.
- Species of CpG adjuvant selected from: TCC ATG ACG TTC CTG ACG TT (SEQ ID NO:1); TCT CCC AGC GTG CGC CAT (SEQ ID NO:2); ACC GAT GAC GTC GCC GGT GAC GGC ACC ACG (SEQ ID NO:3); TCG TCG TTT TGT CGT TTT GTC GTT (SEQ ID NO:4); and TCC ATG ACG TTC CTG ATG CT (SEQ ID NO:5).
- Species of tumor associated antigen selected from MAGE family, PRAME, BAGE, LAGE 1, LAGE 2, SAGE, HAGE, XAGE, PSA, PAP, PSCA, prostatein, P501 S, HASH2, Cripto, B726, NY-BR1.1, P510, MUC-1, Prostase, STEAP, tyrosinase, telomerase, survivin, CASB616, P53, and her 2 neu.

Art Unit: 1645

- Species of infectious disease antigen selected from: Human Immunodeficiency virus HIV-1, human herpes simplex viruses, cytomegalovirus, Rotavirus, Epstein Barr virus, Varicella Zoster Virus, from a hepatitis virus such as hepatitis B virus, hepatitis A virus, hepatitis C virus and hepatitis E virus, from Respiratory Syncytial virus, parainfluenza virus, measles virus, mumps virus, human papilloma viruses, flaviviruses or Influenza virus, from *Neisseria* spp, *Moraxelia* spp, *Bordetella* spp; *Mycobacterium* spp., including *M. tuberculosis*; *Escherichia* spp, including enterotoxigenic *E. coli*; *Salmonella* spp.; *Listeria* spp; *Helicobacter* spp; *Staphylococcus* spp., including *S. aureus*, *S. epidermidis*; *Borrelia* spp; *Chlamydia* spp., including *C. trachomatis*, *C. pneumoniae*; *Plasmodium* spp., including *P. falciparum*; *Toxoplasma* spp., and *Candida* spp.
- Species of adjuvant selected from: 3D-MPL, QS21, a mixture of QS21 and cholesterol, aluminium hydroxide, aluminium phosphate, tocopherol, and an oil in water emulsion. Applicants are directed to elect a single adjuvant or a single combination of adjuvants.

For Group I, applicants' are requested to elect a single CpG sequence and a single infectious disease antigen.

For Group II, applicants' are requested to elect and identify a single disease condition and a single CpG sequence and if cancer is chosen, a single tumor associated antigen or if infectious disease is chosen, a single infectious disease antigen.

For Group III, applicants' are requested to elect a single disease condition and a single adjuvant or a combination of adjuvants and a single CpG and if cancer is chosen, a single tumor associated antigen or if infectious disease is chosen, a single infectious disease antigen.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:

The CpG adjuvants have different sequences and therefore lack a common technical feature. The infectious disease antigens are derived from different microorganism and therefore lack a common technical feature. The tumor-associated antigens are all different proteins with different amino acids sequences and therefore lack a common technical feature.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Effective November 1, 2007, if applicant wishes to present more than 5 independent claims or more than 25 total claims in an application, applicant will be required to file an examination support document (ESD) in compliance with 37 CFR 1.265 before the first Office action on the merits (hereafter "5/25 claim threshold"). See Changes to Practice for Continued Examination Filings, Patent Applications Containing Patentably Indistinct Claims, and Examination of Claims in Patent Applications, 72 Fed. Reg. 46715 (Aug. 21, 2007), 1322 Off. Gaz. Pat. Office 76 (Sept. 11, 2007) (final rule). The changes to 37 CFR 1.75(b) apply to any pending applications in which a first Office action on the merits (FAOM) has not been mailed before November 1, 2007. Withdrawn claims will not be taken into account in determining whether an application exceeds the 5/25 claim threshold. For more information on the final rule, please see <http://www.uspto.gov/web/offices/pac/dapp/opla/presentation/clmcontfinalrule.html>.

In response to the restriction requirement set forth in this Office action, applicant is required to file an election responsive to the restriction requirement. Applicant may not file a suggested restriction requirement (SRR) in lieu of an election responsive to the

Art Unit: 1645

restriction requirement as a reply. A SRR alone will not be considered a *bona-fide* reply to this Office action.

If applicant elects an invention that is drawn to no more than 5 independent claims and no more than 25 total claims, applicant will not be required to file an ESD in compliance with 37 CFR 1.265 that covers each of the elected claims. If the elected invention is drawn to more than 5 independent claims or more than 25 total claims, applicant may file an amendment canceling a number of elected claims so that the elected invention would be drawn to no more than 5 independent claims and no more than 25 total claims.

If the restriction requirement is mailed on or after November 1, 2007, applicant is also required to file an ESD in compliance with 37 CFR 1.265 that covers each of the elected claims, unless the elected invention is drawn to no more than 5 independent claims and no more than 25 total claims taking into account any amendment to the claims. To avoid the abandonment of the application, the ESD (if required) and the election must be filed within **TWO MONTHS** from the mailing date of this Office action. The two-month time period for reply is extendable under 37 CFR 1.136.

If the restriction requirement is mailed before November 1, 2007, the election must be filed within **ONE MONTH** or THIRTY DAYS, whichever is longer, from the mailing date of this Office action. The time period for reply is extendable under 37 CFR 1.136.

Furthermore, if the elected invention is drawn to more than 5 independent claims or more than 25 total claims taking into account any amendment to the claims, the Office will notify applicant and provide a time period in which applicant is required to file an ESD in compliance with 37 CFR 1.265 covering each of the elected claims or amend the application to contain no more than 5 independent elected claims and no more than 25 total elected claims.

Art Unit: 1645

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Oluwatosin Ogunbiyi whose telephone number is 571-272-9939. The examiner can normally be reached on M-F 7am-4pm.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campbell can be reached on 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Tosin Ogunbiyi

Examiner Art Unit 1645



PATRICIA A. DUFFY
PRIMARY EXAMINER